ABL Bio's gastric cancer drug Givastomig shrinks tumors by 79%, advancing phase 3 preparations
Predicted impact: Medium
Same Givastomig 79% tumor shrinkage data already reported; phase 3 prep is incremental.
ABL Bio에이비엘바이오
298380 · KOSDAQ · ₩298380 · 에이비엘바이오
₩41,000▼ ₩800 (1.91%)End-of-day · Oct 29, 2026 · End-of-day prices.
ABL Bio's gastric cancer candidate shows tumor reduction in 79% of treated patients
Predicted impact: Medium
Clinical data on ABL111 already covered at ESMO this fortnight; 79% tumor reduction restates it.
ABL Bio Announces Additional Clinical Data for ABL111 and ABL503, Pushes Ahead with Follow-on Development
Predicted impact: Low
ESMO clinical data presentation already announced in the last 14 days.
ABL Bio presents results of two bispecific antibodies at ESMO
Predicted impact: Low
Conference data presentation already previewed; routine clinical update.
ABL Bio presents clinical data on two bispecific antibodies at ESMO
Predicted impact: Low
Clinical data presentation was pre-announced in the last 14 days; early-stage drug data, small impact.
ABL Bio to unveil clinical data on two bispecific antibody immuno-oncology drugs at ESMO
Predicted impact: Medium
Clinical data on two bispecific antibody drugs at ESMO; pipeline news for a firm with tiny revenue.
ABL Bio to announce ABL111 and ABL503 data this month: "Expanding clinical trials"
Predicted impact: Medium
Clinical trial data release for two drug candidates expected this month, a meaningful catalyst.
Also known as: ABL Bio / 에이비엘바이오 / 298380 / KRX:298380
Source: KRX statistical information